Role of Tumor Stroma in Therapeutic Response and Resistance

肿瘤基质在治疗反应和耐药中的作用

• 批准号: 8540403
• 负责人: LYNDA CHIN
• 金额: $ 95.46万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8540403
• 关键词: Accounting; Address; Aftercare; Area; Automobile Driving; BAY 54-9085; BRAF gene; Basic Science; Biology; CTLA4 gene; Cells; Clinic; Clinical; Clinical Research; Clinical Trials; Communication; Computational Science; Data; Disease; Ensure; Future; Generations; Genetic; Genetically Engineered Mouse; Genomics; Human; Immune; Immunology; Immunosuppression; Immunotherapy; In Vitro; In complete remission; Instruction; Life; Malignant Neoplasms; Melanoma Cell; Metastatic Melanoma; Modeling; Mus; Mutation; Oncogenes; Pathogenesis; Pathway interactions; Patients; Phase; Play; Progression-Free Survivals; Proteomics; Regimen; Regulatory Pathway; Relapse; Research; Resistance; Resource Sharing; Role; Sampling; Stromal Neoplasm; Testing; Therapeutic; Time; Translational Research; Ursidae Family; advanced disease; cancer genomics; chemotherapy; clinical efficacy; cohort; epigenomics; in vivo; inhibitor/antagonist; melanoma; mouse model; mutant; neoplastic cell; resistance mechanism; response; transcriptomics; tumor; tumor microenvironment

DESCRIPTION (provided by applicant): The single agent efficacy of selective mutant BRAF inhibitors in patients with advanced melanoma is a transformative advance but the uniformly short-lived responses have now defined therapeutic resistance as the central paramount question in the field. While much of the field is focusing on somatic alterations in the melanoma cells that can drive resistance, we hypothesize that the tumor microenvironment plays an active contributory role in dictating the response to therapy initially and in facilitating emergence of resistance over time, hence modulating tumor-stromal alterations together with targeted therapy is a rational combination strategy to minimize emergence of resistance. To address this systematically, we have brought together this U54 team with diverse but complementary expertise in clinical, translational and basic research in areas of melanoma biology and genetics, immunology and cancer genomics to pursue the following two highly inter dependent and interrelated projects. Project 1: Identification of resistance-conferring stromal alterations i BRAF mutant melanoma. Here, global unbiased profiling on transcriptomic, epigenomic and proteomic levels in BRAF mutant human melanomas and derivative cells at baseline, post-treatment and upon relapse on selective BRAF inhibitor, compared with similar analyses in genetically engineered mouse models, will identify candidate stromal alterations associated with resistance that are dependent on tumor stromal interactions. Functional relevance of these candidates will be validated through genetic or pharmacological perturbation in vitro and in vivo while human relevance will be confirmed through analysis of larger cohort of human samples. Finally, mechanism of action will be explored to support possible strategy of modulating such stromal components to minimize resistance. Project 2: Roles of immune regulatory pathways in resistance to BRAF targeted therapy. Clinical efficacy of immune-inhibitory pathway blockade in human melanoma, supported by preliminary data in human and mouse, has pointed to an active role for immunosuppression in melanoma pathogenesis. This project will study the roles of immune regulatory pathways (through molecules such as CTLA4 and PD-L1) in melanoma and explore the consequences of such modulation on therapeutic response. The two Shared Resource Cores on "Clinically annotated human melanoma for TMEN research" and "GEM models for TMEN research" will not only support activities of these two projects but are expected to be high impact enablers for the entire research network. Finally, this U54 team brings to TMEN a diverse set of unique capabilities that can be leveraged for studies of the tumor microenvironment Thus, in addition to ensuring close interaction and coordination of complementary activities within this center, the 'Administrative Core' will also be responsible for efficient and effective communication and interaction with the TMEN research network.

描述（由申请人提供）：选择性突变BRAF抑制剂在晚期黑色素瘤患者中的单药疗效是一项变革性进展，但一致的短期应答现已将治疗耐药性定义为该领域的中心首要问题。虽然该领域的大部分都集中在黑色素瘤细胞中可以驱动耐药性的体细胞改变上，但我们假设肿瘤微环境在最初决定对治疗的反应和随着时间的推移促进耐药性的出现方面起着积极的贡献作用，因此调节肿瘤基质改变与靶向治疗一起是一种合理的组合策略，以最大限度地减少耐药性的出现。为了系统地解决这一问题，我们汇集了U 54团队，他们在黑色素瘤生物学和遗传学，免疫学和癌症基因组学领域的临床，转化和基础研究方面具有多样但互补的专业知识，以追求以下两个高度相互依赖和相互关联的项目。项目1：鉴定BRAF突变型黑色素瘤中赋予耐药的基质改变。在此，与基因工程小鼠模型中的类似分析相比，在基线、治疗后和选择性BRAF抑制剂复发时，BRAF突变型人黑色素瘤和衍生细胞中转录组、表观基因组和蛋白质组水平的全局无偏分析将鉴定与依赖于肿瘤基质相互作用的耐药性相关的候选基质改变。这些候选物的功能相关性将通过体外和体内遗传或药理学扰动进行验证，而人类相关性将通过分析更大的人类样本队列进行确认。最后，将探讨作用机制，以支持可能的策略，调节这些基质成分，以尽量减少阻力。项目2：免疫调节途径在BRAF靶向治疗耐药中的作用。在人类和小鼠中的初步数据支持的免疫抑制途径阻断在人类黑色素瘤中的临床疗效已经指出免疫抑制在黑色素瘤发病机制中的积极作用。该项目将研究免疫调节途径（通过CTLA 4和PD-L1等分子）在黑色素瘤中的作用，并探索这种调节对治疗反应的影响。关于“用于TMEN研究的临床注释人类黑色素瘤”和“用于TMEN研究的GEM模型”的两个共享资源核心不仅将支持这两个项目的活动，而且预计将成为整个研究网络的高影响力推动者。最后，这个U 54团队为TMEN带来了一系列独特的能力，可以用于肿瘤微环境的研究。因此，除了确保该中心内互补活动的密切互动和协调外，“行政核心”还将负责 与TMEN研究网络进行高效和有效的沟通和互动。